+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial



Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial



Circulation 113(10): 1287-1294



Intracoronary transfer of autologous bone marrow cells (BMCs) may enhance recovery of left ventricular (LV) function in patients after acute myocardial infarction (AMI). However, clinical studies addressing the effects of BMCs after AMI have covered only limited time frames ranging from 3 to 6 months. The critical question of whether BMC transfer can have a sustained impact on LV function remains unanswered. After percutaneous coronary intervention with stent implantation (PCI) of the infarct-related artery, 60 patients were randomized 1:1 to a control group with optimal postinfarction therapy and a BMC transfer group that also received an intracoronary BMC infusion 4.8+/-1.3 days after PCI. Cardiac MRI was performed 3.5+/-1.5 days, 6+/-1 months, and 18+/-6 months after PCI. BMC transfer was not associated with adverse clinical events. In the control group, mean global LV ejection fraction increased by 0.7 and 3.1 percentage points after 6 and 18 months, respectively. LV ejection fraction in the BMC transfer group increased by 6.7 and 5.9 percentage points. The difference in LVEF improvement between groups was significant after 6 months but not after 18 months (P=0.27). The speed of LV ejection fraction recovery over the course of 18 months was significantly higher in the BMC transfer group (P=0.001). In this study, a single dose of intracoronary BMCs did not provide long-term benefit on LV systolic function after AMI compared with a randomized control group; however, the study suggests an acceleration of LV ejection fraction recovery after AMI by BMC therapy.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012231291

Download citation: RISBibTeXText

PMID: 16520413

DOI: 10.1161/circulationaha.105.575118


Related references

Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. European Heart Journal 30(24): 2978-2984, 2009

Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 364(9429): 141-148, 2004

Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial. European Heart Journal 38(39): 2936-2943, 2017

Long-term effects of intracoronary bone marrow cell transfer on diastolic function in patients after acute myocardial infarction: 5-year results from the randomized-controlled BOOST trial--an echocardiographic study. European Journal of Echocardiography 11(2): 165-171, 2010

Impact of intracoronary bone marrow cell transfer on diastolic function in patients after acute myocardial infarction: results from the BOOST trial. European Heart Journal 27(8): 929-935, 2006

Efficacy and safety of intracoronary autologous bone marrow-derived cell transplantation in patients with acute myocardial infarction: insights from randomized controlled trials with 12 or more months follow-up. Clinical Cardiology 33(6): 353-360, 2010

Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Yearbook of Cardiology 2007: 215-217, 2007

Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 367(9505): 113-121, 2006

Influence of bone marrow stem cells on left ventricle perfusion and ejection fraction in patients with acute myocardial infarction of anterior wall: randomized clinical trial: Impact of bone marrow stem cell intracoronary infusion on improvement of microcirculation. European Heart Journal 31(6): 691-702, 2010

Safety and efficacy of intracoronary hypoxia-preconditioned bone marrow mononuclear cell administration for acute myocardial infarction patients: The CHINA-AMI randomized controlled trial. International Journal of Cardiology 184: 446-451, 2015

Intracoronary autologous bone marrow cell transfer for myocardial infarction: a safe procedure?. Cardiovascular Journal of Africa 20(4): 227, 2009

Clinical trials of intracoronary bone marrow cell transfer after myocardial infarction: the Hannover experience. Biology of Blood and Marrow Transplantation 11(2 Suppl 2): 7-8, 2005

Intracoronary autologous bone marrow cell transfer after acute myocardial infarction: abort and refocus. European Heart Journal 38(39): 2944-2947, 2017

GW26-e0740 Safety and Efficacy of IntraCoronary Hypoxia-precondItioned Bone Marrow MonoNuclear Cell Administration for Acute Myocardial Infarction Patients: The CHINA-AMI Randomized Controlled Trial. Journal of the American College of Cardiology 66(16): C79-C80, 2015

Intracoronary infusion of autologous bone marrow cells after myocardial infarction Results of a prospective randomized-controlled clinical Trial. Blood 102(11): 335a, 2003